GlassScriptPhysician profile
Gordon Lee Lerch
NPI 1790885275
$611.68
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $198 · 2021: $207 · 2022: $84.54.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $155.19 | 2019-2022 | |
| Tris Pharma INC | $106.99 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.04 | 2020-2022 | |
| Kaleo, INC. | $69.26 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $55.34 | 2020-2022 | |
| Sanofi Pasteur INC. | $49.13 | 2021-2022 | |
| Adlon Therapeutics L.P. | $27.72 | 2020-2021 | |
| Biogen, INC. | $21.47 | 2021 | |
| Cranial Technologies, INC | $16.84 | 2020 | |
| Sobi, INC | $14.02 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.48 | 2019 | |
| Genentech USA, INC. | $12.20 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Lerch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.